Disclosures for "Elevated Cerebrospinal Fluid CXCL13 Helps Predict Relapse Risk in Myelin Oligodendrocyte Glycoprotein Antibody Associated Disorders (MOGAD)"
-
Dr. Karbhari has nothing to disclose.
-
-
The institution of Dr. Gilli has received research support from NIH -NINDS.
-
Dr. DiSano has nothing to disclose.
-
Dr. Smith has nothing to disclose.
-
Dr. Robbins has received personal compensation in the range of $0-$499 for serving as a Consultant for Red Nucleus. Dr. Robbins has received personal compensation in the range of $0-$499 for serving as a Consultant for TDG Health. Dr. Robbins has received personal compensation in the range of $0-$499 for serving as a Consultant for Jupiter Life Science Consulting. Dr. Robbins has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Vickery & Shepherd. Dr. Robbins has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for Vaccine Injury Compensation Program. The institution of Dr. Robbins has received research support from Diamond Endowment Fund. The institution of Dr. Robbins has received research support from Reeves Endowment Fund. The institution of Dr. Robbins has received research support from Institute for Ethnomedicine. The institution of Dr. Robbins has received research support from Vertex Pharmaceuticals . Dr. Robbins has received personal compensation in the range of $50,000-$99,999 for serving as a Neurohospitalist with Hayes Locums.